Potential impact of consolidation radiation therapy for advanced Hodgkin Lymphoma: a secondary modeling analysis of SWOG S0816
Baseline PET features as predictors of outcome in advanced HL : A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033)
B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)
09:15 – 10:15
Room: Großer Saal
(by Celgene GmbH)
CAR T Cell Therapies: Hype Or Hope?
Second Autologous Stem Cell Transplantation (ASCT) for Relapsed or Refractory (R/R) Hodgkin Lymphoma (HL) after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Bendamustine, Gemcitabine, and Dexamethasone (BGD) Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) Is Effective Treatment for Patients with Relapsed/Refractory Hodgkin Lymphoma (rHL) – Results of the Polish Lymphoma Research Group
Long Term Safety and Efficacy of Combination of Brentuximab Vedotin and Ipilimumab or Nivolumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412)
PD-1 blockade for Hodgkin Lymphoma after Allogeneic Stem Cell Transplantation
Five-Year Progression-Free Survival Outcomes From a Pivotal Phase 3 Study of Consolidative Brentuximab Vedotin After Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression (AETHERA).
Craig H. Moskowitz
Relapse after Early-Stage Favorable Hodgkin Lymphoma: Disease Characteristics, Treatment Strategies and their Outcome